Complex Care Curriculum: Autonomic Dysreflexia by Beck, Jimmy & Conroy, Rebekah
Complex Care 
Curriculum Autonomic Dysreflexia
Jimmy Beck, MD
Rebekah Conroy, MD
Complex Care 
Curriculum Autonomic Dysreflexia
1)Define Autonomic Dysreflexia (AD) in 
simple terms
2)Describe the pathophysiology
3)List the life threatening complications
4)List the most common precipitants
5)List signs and symptoms
6)Formulate an acute management plan 
using both non-pharmacologic and 
pharmacologic treatment options
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Clinical phenomenon with life threatening potential
∙ Patients with spinal cord injuries
Location of injury
∙ At over above T-6 Level
Incidence
∙ 16% of children and adolescents
Timeframe
∙ 2-6 months after injury
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Noxious 
stimuli
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Cerebral 
Hypertension
Hemorrhage
Seizures
Pulmonary 
Edema
Arrhythmias
Coma
Death
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• Bladder distension
• Kidney stones
• Blocked catheter
• Catheterization
• Instrumentation 
• Urinary tract infection
GENITOURINARY
• Bowel distension due to 
fecal impaction
• Appendicitis
• Gallstones
• Gastric ulcers or gastritis
• Anal fissure
• Enema or suppository
• Barium enema
• Colonoscopy
GASTROINTESTINAL
Bladder issues account for 
75-85% of AD episodes.
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• Constrictive clothing
• Contact with sharp 
objects
• Blister
• Burn
• Frostbite
• Ingrown toenail
• Insect bite
• Pressure ulcer
DERMATOLOGY
• Labor and delivery
• Menstruation
• Intercourse
• Ejaculation
• STD
• Scrotal compression
• Epididymitis
• Vaginitis
REPRO. SYSTEM
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• Pulmonary 
embolism
• Deep vein 
thrombosis
HEMATOLOGY
• Fracture
• Trauma
• Joint dislocation
MUSCULOSKELETAL
• Excessive alcohol 
intake
• Excessive caffeine
• Excessive diuretic 
intake
• Nasal 
decongestants
• Sympathomimetics
MEDS
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SYMPTOMS
• Anxiety
• Pounding headache
• Blurry vision 
• Nasal congestion
• Metallic taste in mouth
• Respiratory distress
• Nausea
• Urge to void
• Increased spasticity
• Parasthesias
SIGNS
• Paroxsymal HTN
• Bradycardia
• Ocular findings 
• Fecal Impaction
• Penile erection
• Diaphoresis of forehead
• Blanching rash on face 
and neck and chest 
• Cutis anserina
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Assess patient: including Temp, HR, BP
Sit patient upright 
Remove any tight clothing 
Recheck HR and BP every 5mins
If febrile, remove any external temperature sources 
McGinnis et al. J Spinal Cord Med. 2004.
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Mild – Moderate HTN
• ≤ 13yrs: SBP ≥ 15-30 
mmHg above baseline
• > 13yrs: SBP ≥ 20 mmHg 
above baseline up to 
150mmHg
Severe HTN
• ≤ 13yrs: SBP >30mmHg 
above baseline
• > 13yrs: SBP >150mmHg
Non-pharmacologic management will 
resolve the majority of AD episodes.
McGinnis et al. J Spinal Cord Med. 2004.
Non-pharmacologic   
Treatment
Pathophysiology
Learning Objectives
Severe Complications
Definition
Initial Assessment
Precipitants
Clinical Manifestations
Acute Management 
Algorithm
Pharmacologic 
Treatment
Summary
References
Drug Formulary
Complex Care 
Curriculum Autonomic Dysreflexia
Mild to Moderate 
Blood Pressure Elevation
Repeat vital signs
Perform bowel management steps. 
Consider hypertension medications.
Perform bladder management steps
If blood pressure elevation 
becomes severe, transfer to ICU
If BP decreases, monitor  
until VS normal & patient 
asymptomatic
If BP remains unchanged or 
increases, notify MD 
McGinnis et al. J Spinal Cord Med. 2004.
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Severe Blood Pressure Elevation
Notify MD
Consider nifedipine or nitropaste
Perform bladder management steps* 
Place patient on monitor
If BP remains elevated, perform bowel management steps,* 
and start hypertension medications if not previously done
If BP elevation remains severe, prepare for transfer to ICU
McGinnis et al. J Spinal Cord Med. 2004.
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If Foley present
Remove any kinks
If plugged, irrigate with 5-10 ml of sterile normal 
saline for kids < 2 yrs and 10-15 ml for kids > 2 yrs
If remains plugged, remove it and insert 2% 
xylocaine jelly into urethra. Wait 2 minutes and 
insert new foley catheter using jelly as lubricant
Avoid manually compressing or tapping on 
bladder
If no Foley
Insert 2% xylocaine jelly into urethra. Wait 2 
minutes and insert Foley catheter using jelly as 
lubricant
Avoid manually compressing or tapping on 
bladder
Leave catheter in place if difficult catheterization
McGinnis et al. J Spinal Cord Med. 2004.
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Insert 2% xylocaine jelly into rectum
Wait 2 minutes and examine rectum, 
checking for presence of stool
Remove any stool if present
If  autonomic dysreflexia does not resolve or 
blood pressure continues to increase
Stop manual evacuation and instill additional 
2% xylocaine jelly
After 20 minutes, recheck for presence of 
stool and remove if present
McGinnis et al. J Spinal Cord Med. 2004.
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?
Nitropaste
Nifedipine
Clonidine
Hydralazine
Long acting medications are not 
indicated in the management
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Nitroglycerin paste
Rapid onset, reversible
Venous pooling and the drop in BP may 
trigger an alpha agonist release thereby 
exacerbating the AD
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Nifedipine
Rapid onset
May cause headache, tachycardia, 
dizziness, fatigue, nausea, or orthostatic 
hypotension
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Hydralazine
Rapid onset, titratable
May cause reflex tachycardia, prolonged 
hypotension, nausea. 
Requires IV access 
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Clonidine
Rapid onset with oral form
Withdrawal can cause life threatening 
hypertension
Non-pharmacologic   
Treatment
Pathophysiology
Learning Objectives
Severe Complications
Definition
Initial Assessment
Precipitants
Clinical Manifestations
Acute Management 
Algorithm
Pharmacologic 
Treatment
Summary
References
Drug Formulary
Complex Care 
Curriculum Autonomic Dysreflexia
Other Medications
• Phenoxybenzamine
• Prazosin 
• Mecamylamine
• Oxybutynin
• Nitroprusside
• Diazoxide
• Trimethaphan camphorsulfonate
• Phentolamine  
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Non-Pharmacologic
• Identify and remove 
the noxious stimuli
• Bladder issues are the 
most common trigger 
followed by GI issues
Pharmacologic
• Nitroglycergin paste
• Nifedipine
T6
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Please take note of the following prior to using this 
formulary:
 Most of these medications are not FDA approved for the treatment 
of dysautonomia, particularly in the pediatric population.  
 The dosage information provider here is a combination of 
recommendations from the Pediatric Dosing Handbook Formulary
and expert opinion.  
 It is important for this dosing information to be used with caution 
and only after full review of the entire dysautonomia module.
 We highly encourage you to discuss medication dosing with a 
pharmacist and/or pediatric physiatrist if you have any questions or 
concerns.
Continue to Drug Formulary
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Nitroglycerin
Mechanism of 
Action
Direct acting vasodilator; causes dilation of the 
venous system; decreases preload of the heart
Dose •Nitroglycerin 2% paste:  Start with 0.5 inch and 
increase by 0.5 inch increments to achieve desired 
results. Apply topically 1 inch above the spinal cord 
injury level (max of 2 doses/day)
•Sublingual (adults): 0.3-0.6 mg q5 minutes (max of 3 
doses in 15 minutes)
Onset 10-30 minutes
Duration 3-6 hours; may wipe away paste to stop action
Precautions May aggravate AD by reflexively increasing 
sympathetic alpha agonist release secondary to 
venous pooling and drop in BP
Dosage Forms Topical: 2% ointment
SL: 0.3 mg, 0.4 mg, 0.6 mg tablets
ClonidineHydralazineNifedipineCapsuleNifedipineNitroglycerin
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Nifedipine
Mechanism of 
Action
Calcium channel blocker; potent coronary and 
peripheral arterial vasodilator
Dose Children: 0.25-0.5mg/kg/dose (max 10 mg), 
may repeat every 4-6 hours as needed
Adult:  10mg chewable
Onset SL/“bite and swallow”: within 1 – 5 minutes
IR: within 20 – 30 minutes
Duration 4 – 8 hours
Precautions May cause headache, tachycardia, dizziness, 
fatigue, nausea, or orthostatic hypotension.  
Ineffective at prevention of episodes.  Do not 
use the sustained release form.  
Dosage Forms 10 mg capsule (contains 10 mg/0.34 mL); liquid 
must be withdrawn from capsule
ClonidineHydralazineNifedipineCapsuleNifedipineNitroglycerin
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Weight (Kg) Dose Range Volume
≥ 10 2.5 mg – 5 mg 0.09 ml – 0.17 ml
≥ 15 3.75 mg – 7.5 mg 0.13 ml – 0.26 ml
≥ 20 5 mg – 10 mg 0.17 ml – 0.34 ml
≥ 30 7.5 mg – 10 mg 0.26 ml – 0.34 ml
≥ 40 10 mg 0.34 ml
Nifedipine Capsule: 
10 mg contains 0.34 mL
McGinnis et al. J Spinal Cord Med. 2004.
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Hydralazine
Mechanism of 
Action
Relaxes smooth muscle; causes peripheral 
vasodilation.  
Dose IV push:  0.1-0.2 mg/kg/dose IM/IV every 4-6 
hours as needed (max dose 20mg/dose).
Onset 5 – 20 minutes
Duration 2 – 6 hours
Precautions May cause tachycardia, vomiting, flushing and 
headache. May give with diuretic and a beta-
blocker to counteract side effects of sodium 
and water retention and reflex tachycardia.
Concentration 20 mg/mL
ClonidineHydralazineNifedipineCapsuleNifedipineNitroglycerin
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Clonidine
Mechanism of 
Action
Alpha-2 agonist; decreases sympathetic outflow from 
CNS; peripheral vascular resistance, heart rate, blood 
pressure, and renal vascular resistance.
Dose 1-17 years old: 0.05 – 0.1 mg/dose (may repeat 
hourly up to max total dose 0.8 mg)
< 1 year old: not recommended (could use dose of 
2.5 mcg/kg/dose if no other options)
Onset 30 – 60 minutes
Duration 6 – 10 hours
Precautions Serious bradycardia may occur if given with other 
sympatholytic drugs. Rebound hypertension may 
develop with abrupt withdrawal. May also cause 
sedation and CNS side effects.
Dosage Forms 0.1 mg tablet
ClonidineHydralazineNifedipineCapsuleNifedipineNitroglycerin
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